This study addressed the dearth of information on the incidence of psychiatric disorders related to corticosteroid-containing treatment in patients with hematologic malignancies.
Researchers sought to determine if nonmyeloablative HSCT conditioning was noninferior to myeloablative approaches in more vulnerable patients with AML.
Patients receiving ibrutinib for chronic lymphocytic leukemia experienced an average weight gain of 2.4 kg at 1 year after therapy initiation.
Patients with acute myeloid leukemia and myelodysplastic syndromes reported similar quality of life irrespective of the conditioning regimen the received.
In patients with complete response at transplant, age was found to be the only predictor of clinical outcomes.
This study investigated whether T-cell gene-expression profiles and other molecular characteristics of T-cell populations were associated with CAR-T performance.
Exercise tolerance was found to be associated with verbal fluency, dominant motor speed, and math academics, among other neurocognitive metrics.
Central nervous system relapse rates in pediatric acute lymphoblastic leukemia can be reduced with additional early doses of intrathecal chemotherapy.
Researchers assessed whether high platelet counts in pediatric patients with chronic myeloid leukemia resulted in thrombosis or bleeding.
Patients receiving treosulfan and fludarabine experienced improved event-free and overall survival compared with patients receiving busulfan and fludarabine.
The response rate to 19-28z CAR-T therapy was 100% for those with pretreatment MRD who received preconditioning chemotherapy with high-dose cyclophosphamide.
The risk may be transient, as immune function recovered in late phases of treatment.
Researchers conducted a meta-analysis of 23 studies to determine the influence of measurable residual disease on survival outcomes.
Researchers analyzed long-term safety and efficacy data from patients treated with ibrutinib or ofatumumab in the phase 3 RESONATE trial.
Using EQ-5D and PedsQL, researchers determined the long-term effect of tisagenlecleucel treatment on quality of life for pediatric and young patients with R/R B-cell ALL.
Approximately one-third of patients in each treatment group experienced symptoms of depression and anxiety during treatment.
It is hypothesized that BAFF-R could prevent the emergence of CD19-based antigen loss.
The risk for second primary malignancy appeared to increase over time in survivors of chronic lymphocytic leukemia compared with the general population.
Patients received 50 mg dasatinib daily and demonstrated 2-year rates of overall and event-free survival of 100%.
Researchers conducted a meta-analysis to evaluate possible associations between certain genetic variants and risk for acute lymphoblastic leukemia.
Older age at diagnosis, white race, and body mass index below the fifth percentile were associated with low bone mineral density.
Factors associated with survival in chronic myeloid leukemia diagnosed in advanced phase or blast crisis included blast count, age, and hemoglobin level.
Of patients who experienced vincristine-induced neuropathy, approximately half were identified as having undernutrition.
Infections occurred in 33 of 54 patients for whom data were available, and 80% of infections were treated in an outpatient setting.
Although the 7 + 3 regimen has been the standard of care for acute myeloid leukemia for decades, it may be time to reassess its value and utility.
A retrospective evaluation of patients with leukemia or lymphoma treated with CAR-T therapy determined their likelihood of experiencing refractory colitis associated with the treatment.
A retrospective study evaluated the incidence of respiratory adverse events in children and adolescents with AML who received induction chemotherapy.
Presence of a complex karyotype did not affect progression-free or overall survival.
Using validated assessment tools, researchers compared patients’ perceptions of HRQOL while undergoing treatment for CML with 1 of 2 TKIs.
Researchers are assessing the value and safety of discontinuing TKI therapy in patients with chronic phase CML who have achieved deep molecular response.
A treatment delay of 6 months was found to result in up to a 67.3% loss in social value for patients receiving chimeric antigen receptor T-cell therapy.
Over half of patients with
TP53-mutated acute myeloid leukemia who received the combination therapy experienced a response.
In a review article, researchers discussed maintenance treatment strategies using chemotherapy, immunotherapy, targeted small molecules, and more.
Nilotinib was associated with high adherence to treatment and fairly high quality of life, and nearly all evaluated patients achieved a major molecular response.
Certain malignancies, younger age at diagnosis, and multiple affected relatives were all associated with increased familial relative risks.
This trial employed chemotherapy-free induction therapy followed by assessment of MRD status to triage patients for subsequent therapy with or without chemotherapy.
Further studies needed to look at relevance outside of the transplant-eligible population.
Some patients with BTK mutations could benefit from treatment changes at earlier stages.
As oncologists welcome new chronic lymphocytic leukemia treatments, one researcher creates a scoring system to make the case for transplants.
At 3 years, the rates of overall and leukemia-free survival were 45% and 41%, respectively.
Patients with ADAMTS13 activity below a cutoff of 481 ng/mL had more bone marrow transplant-related complications, according to researchers.
Patients who received ibrutinib and rituximab had a 3-year PFS rate of 89.4%, compared with 72.9% in patients receiving chemoimmunotherapy.
Oncologists are changing the way they treat, perhaps too quickly and with too little evidence — but the behavior may signal a bigger problem with how research is reported.
Median overall survival was 42 months in patients who received sorafenib and 13 months in patients who received chemotherapy alone.
Type of chemotherapy did not result in significant differences in disease-free or overall survival.
The Food and Drug Administration (FDA) has approved Ruxience (rituximab-pvvr; Pfizer), a biosimilar to Rituxan (Genentech and Biogen), for the treatment of adult patients with non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, and granulomatosis with polyangitis and microscopic polyangiitis. The approval was based on a comprehensive data package which included results from the REFLECTIONS B3281006 study in…
Researchers sought to develop a model that can be used to identify patients receiving targeted therapy for CLL who are at high risk for poor outcomes.
Inferior survival for patients with chronic lymphocytic leukemia who progress with lymphadenopathy
Many clinical and ethical factors influence whether preemptive transplant would be beneficial for patients genetically predisposed to acute myeloid leukemia.
An alternative measure of relapse risk is needed in patients for whom no polymerase chain reaction marker is available.
Platelet aggregation and platelet activation were both independently associated with bleeding risk.